Kite, the Santa Monica, California-based cell therapy subsidiary of Gilead, has entered a definitive agreement to pay $350 ...

A University of Pennsylvania spinout that is developing a faster and cheaper way to modify immune cells to fight cancer will be sold to a unit of Gilead Sciences Inc. for $350 million under an ...

Kite has entered into a definitive agreement to acquire Interius BioTherapeutics, a privately held company developing in vivo CAR therapeutics.

The deal gives Gilead ownership of a technology that can genetically modify immune cells inside the body, an approach could ...

Gilead has become the latest pharma to strengthen its in-vivo cell therapy credentials this year, paying $350 million for CAR-T developer Interius BioTherapeutics. | Gilead has become the latest ...

Kite Pharma is acquiring Interius BioTherapeutics for $350 million, adding in vivo CAR T technology that could simplify treatment and expand patient access.

The acquisition aims to expand Kite Pharma’s capabilities in in vivo CAR T-cell therapy research and development.

Gilead subsidiary Kite Pharma said that it has acquired Interius BioTherapeutics and its single-shot CAR-T program for $350 million.

Gilead Sciences agreed to buy Interius BioTherapeutics, a privately held biotechnology company developing in-vivo CAR therapeutics, for $350 million. Gilead on Thursday said the deal complements the ...

Kite, a Gilead Company, has agreed to acquire Interius BioTherapeutics, a privately held biotechnology company developing in vivo CAR therapeutics.

Interius BioTherapeutics Develops Wholly Owned Process for Lentiviral Vector Manufacturing; Leverages WuXi Advanced Therapies' ("WuXi ATU") plasmid and lentiviral vector manufacturing expertise to ...

PHILADELPHIA, May 18, 2021 /PRNewswire/ — Interius BioTherapeutics, a preclinical stage gene therapy company developing a paradigm-shifting platform for in vivo cell-specific gene delivery, t… ...